We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Joint Venture Proton Therapy Center Under Development

By HospiMedica International staff writers
Posted on 27 Feb 2012
A cancer treatment-center project, now under development in the US state of Arizona, is the latest of an ongoing effort to bring cutting-edge treatment technologies to more patients through joint-venture partnerships with physicians and hospitals. More...


Proton therapy is a groundbreaking cancer treatment that targets tumors with a beam of protons. By delivering doses with pinpoint precision, proton therapy is painless, non-invasive, and very effective in treating tumors while minimizing damage to surrounding healthy tissue.

Accelitech, LLC (Rosemont, IL, USA), a developer and manager of full-cycle management of technology-driven cancer treatment programs, recently announced its inaugural proton therapy project. Due to the high cost and large scope of developing a proton therapy center, there are only a small number of places in the United States where patients can receive the treatment. With recent lower cost options entering the market, Accelitech hopes to change that by using its existing model to target several proton therapy locations over the next two years.

“The technology may be new, but our model for success remains the same,” stated Kerwin Brandt, president and CEO of Accelitech. “Proton therapy is the next generation of cancer treatment, and this project is an exciting opportunity to apply our proven, full-cycle management process to making this state-of-the-art technology available to patients on a broader scale.”

Proton beam therapy is a type of external radiotherapy that targets tumors with beams of protons. It has fewer side effects than standard radiation and is proven to be effective in sensitive areas such as the head, spine, and prostate. Because of the exact localization and unique behavior of protons, higher dosages can be delivered with excellent accuracy, sparing more of the healthy tissue that surrounds the tumor. Proton beam therapy is a noninvasive, pain-free procedure that provides a reduced risk of secondary cancer incidents, making it an appealing alternative for the treatment of growing children.

Related Links:

Accelitech



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Electrode Solution and Skin Prep
Signaspray
Exam Table
PF400
Infant Resuscitator
Easypuff
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.